Assessing and accessing the small airways; implications for asthma management by Scichilone, N. et al.
Assessing and accessing the small airways; implications for asthma management
Nicola Scichilone a,*, Marco Contoli b, Davide Paleari c, Pietro Pirina d, Andrea Rossi e,
Claudio Maria Sanguinetti f, Pierachille Santus g, Matteo Soﬁa h, Nicola Sverzellati i
aBiomedical Department of Internal and Specialist Medicine (DIBIMIS), Section of Pneumology, University of Palermo, via Trabucco 180, 90146 Palermo, Italy
b Section of Respiratory Diseases, University of Ferrara, Via Savonarola 9, 44121 Ferrara, Italy
cMedical Department, Chiesi Farmaceutici S.p.A., via Palermo 26/A, 43122, Parma, Italy
dUOC di Pneumologia, AOU di Sassari, Viale San Pietro, 07100 Sassari, Italy
eUOC Pneumologia, AOUI, Ospedale Maggiore di Borgo Trento, Piazzale Stefani 1, 37126 Verona, Italy
fQuisisana Clinical Center, Via Catone 29, 00192 Roma, Italy
gUniversità degli Studi di Milano, Dipartimento di Scienze della Salute, Pneumologia Riabilitativa-Fondazione Salvatore Maugeri-Istituto Scientiﬁco di Milano-IRCCS, Via Camaldoli
64, 20138 Milano, Italy
hClinica Pneumologica Federico II Ospedale Monaldi, Via L. Bianchi, 80131 Napoli, Italy
i Scienze Radiologiche, Padiglione Barbieri, Azienda Ospedaliero-Universitaria di Parma, 43100 Parma, Italy
a r t i c l e i n f o
Article history:
Received 8 May 2012
Received in revised form
1 October 2012
Accepted 6 October 2012
Keywords:
Asthma
Peripheral airways
Small airways
Inﬂammation
Imaging
Extraﬁne
a b s t r a c t
Despite the wealth of experience in the management of asthma, the disease remains inadequately
controlled in some patients, who face long-term respiratory impairment and disability. The disease has
been characterised as an inﬂammatory condition affecting ﬁrst the larger airways and eventually the
smaller airways, but there is evidence that peripheral airway involvement deﬁnes a particular and more
severe phenotype of asthma. For this reason, assessing functional and biological parameters reﬂective of
small airways involvement is important prognostically. No assessment method is universally and directly
representative of peripheral airway function, but the traditional spirometric tests, including vital
capacity, residual volume and forced vital capacity, are somewhat correlated with this function; useful
methods for further assessment include the single-breath nitrogen wash-out test, impulse oscillometry,
nitrous oxide and exhaled breath concentrate measurements, as well as computed tomography to reﬂect
air trapping and response to treatment. Formulation advancements have made for easier treatment
access to the smaller airways, with the new extraﬁne formulations resulting in better asthma control
compared with non-extraﬁne formulations.
! 2012 Elsevier Ltd. All rights reserved.
1. The role of small airways in asthma: old concepts and new
challenges
The prevalence of asthma, which affects up to 10% of adults and
35% of children, is increasing worldwide [1,2]. The disease remains
inadequately controlled on currently available therapies in a large
proportion of patients [3], despite a deeper understanding and
growing knowledge of the pathology, and attention and adherence
to detailed treatment guidelines [4]. The consequences of this
inadequate control of the disease are long-term respiratory
impairment and disability [2,5,6].
The role of the peripheral airways in asthma is increasingly
being recognized as a relevant target (Fig. 1) for asthma treatment
[7,8]. The contribution of small airways to the pathophysiology of
asthma, combined with the presence of the relevant receptors in
these airways, suggests that this site should not be neglected in
the monitoring of asthma or in the development of treatments for
the disease [9]. Asthma is a chronic inﬂammatory disease of the
airways including the most peripheral ones. There is abundant
evidence that inﬂammatory and functional abnormalities of the
lung periphery occur in all stages of the disease from the mildest
[10,11] to the most severe form [12,13]. Interestingly, a correlation
between disease severity and the magnitude of small airway
impairment has been documented [14]. The question arises as to
whether peripheral airways are a site of structural and functional
alterations in asthma irrespective of the clinical manifestation or
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does the involvement of the peripheral airways in asthma repre-
sent a speciﬁc phenotype of the disease that leads to more severe
manifestations, poor clinical control and/or poor response to
treatment. From a purely speculative perspective, the distinction
carries pathophysiological implications: in the ﬁrst case, the alter-
ations of the peripheral airways do not describe themost important
pathogenetic features of asthma but merely represent the conse-
quence of the disease progression. On the other hand, if the path-
ophysiological changes of the peripheral airways are considered as
deﬁning a phenotype of asthma, it is logical to assume that, at least
in this group of asthmatics, the peripheral airway involvement is
a relevant pathogenetic mechanism. Speciﬁcally designed studies
are needed to clarify the matter.
From a clinical standpoint, the identiﬁcation of a speciﬁc asthma
phenotype characterised by prevalent small airway impairment
advocates the need for functional and biological tools that can
accurately assess the peripheral area of the lung. Most importantly,
assessing and accessing the peripheral airways becomes manda-
tory when the small airway involvement potentially carries prog-
nostic implications. From this perspective, the identiﬁcation
of: i) asthma phenotypes characterised by enhanced small airway
impairment and, ii) the link between poor control/asthma severity
and small airway abnormalities, raises the question whether
pharmacological approaches able to increase drug deposition
within the airways will result in further clinical beneﬁt in these
patients.
In the ﬁeld of asthma, the concept of “future risk” is gaining
increasing importance in the management of the disease, as
emphasized by recent guidelines [2]. Whether the detection of
small-airway abnormalities indicates those patients at major risk of
asthma attacks or more severe disease, or predicts those likely to
beneﬁt from a speciﬁc intervention, is unknown and should be
pursued in future studies.
The following sections will discuss the pathology of peripheral
airways in asthma, methods of assessment of the peripheral
airways function, and formulation advancements for better drug
delivery throughout the airways.
2. Peripheral airways pathology: the strength of evidence
Evidence accumulating in recent decades indicates that
inﬂammatory changes of the proximal airways of asthmatics also
occur in the distal airways [15]. The assessment of the distal tract of
the bronchial tree has always been a difﬁcult task due to its relative
inaccessibility. However, with the improvement of bronchoscopic,
morphometric and immunohistochemical techniques, a better
evaluation of airways less than 2 mm in diameter has been made
possible [16]. It is now accepted that inﬂammation is present
throughout the bronchial tree of asthmatics; this inﬂammatory
process is characterized by the presence of activated T lymphocytes
and activated eosinophils, increased mucus plugging obstructing
the lumen, and smooth muscle hyperplasia [17]. In a study
designed to evaluate the inﬂammatory changes of large and small
airways on lung tissue obtained from surgical resections of asth-
matic subjects, the number of activated eosinophils was signiﬁ-
cantly greater in the distal portion of the airways and in the context
of the alveolar walls [11,18].
Additional studies performed in asthmatics conﬁrmed that the
inﬂammatory changes to the peripheral airways parallel the
severity of the disease. In a study by Carroll et al. [19], the increased
expression of mast cell chymase in the outer area of the distal
airways was signiﬁcantly associated with impaired lung function in
individuals with severe asthma. In subjects with severe asthma
compared with those with mild to moderate asthma, an increased
production of alveolar nitric oxide (NO), but not bronchial NO, was
also found [20], implying that a more intense degree of inﬂam-
mation occurs in the periphery of the bronchial tree in the most
severe forms of asthma.
In patients with severe or fatal asthma, there is increased
thickness of the airway smooth muscle layer in the proximal and
distal airways and increased smooth muscle cell size [21]. Recent
ﬁndings suggest that parenchymal abnormalities may also affect
airﬂow obstruction in asthmatics [13]. Indeed, a loss of alveolar
attachments was demonstrated in association with a reduction in
lung elastic recoil, leading to airway collapse. In patients with
Fig. 1. Schematics of the human respiratory system [83]. (Reproduced with permission from Kleinstreuer C, Zang Z, Donohue JF. & Zhang Z. Targeted drug-aerosol delivery in the
human respiratory system. Annu Rev Biomed Eng. 2008; 10:195e220. published by Annual Reviews).
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severe asthma, the progressive loss of lung function is caused by
structural alterations and remodelling of the proximal and distal
airways, and destruction of lung parenchyma [22].
Speciﬁc abnormalities of the distal airways and lung paren-
chyma have also been described in nocturnal asthma, which occurs
in 30e75% of the asthmatic population [23]. In nocturnal asthma,
but not in non-nocturnal asthma, a more pronounced inﬂammation
in the peripheral airways rather than in the large central airways
was described, with a signiﬁcant increase in lymphocytes, macro-
phages and eosinophils during the night [24]. The percentage of
eosinophils and macrophages was also signiﬁcantly increased in
the alveolar tissue and was related to a nocturnal reduction in lung
function. The inﬂammatory response observed in the context of the
alveolar tissue could explain the loss of airways-parenchyma
coupling detected in individuals with nocturnal asthma [25].
3. Assessing the peripheral airways: from the research
perspective to clinical practise
Methods of peripheral airways assessment include lung func-
tion tests, measurements of biomarkers, and imaging techniques.
However, no universally accepted criteria for these tests have been
proposed as being directly representative of peripheral airways
involvement, and changes in these parameters have not yet been
proven to affect the clinical outcomes of patients with asthma [7,8].
3.1. Functional assessment of peripheral airways
Commonlyemployed spirometric tests, such as forced expiratory
volume in 1 s (FEV1) and the ratio of FEV1 to forced vital capacity
(FEV1/FVC), generally reﬂect large airways function and loss of lung
elastic recoil [26,27]. Measures of lung volumes, such as vital
capacity (VC), residual volume (RV) and forced vital capacity (FVC)
are, to some extent, correlated to the functional state of the
peripheral airways. VC is reduced in patients with peripheral
airways obstruction, and this reductionmay occur before that of the
FEV1/VC ratio [26]. RV is increased in patients with air trapping,
a phenomenon that is secondary to alterations that mainly occur at
the level of peripheral airways [7]. FVC is reduced at any level of
airwayobstruction, butmaybe also a reﬂection of air trapping [7]. In
the late nineties, spirometric pattern characterized by a decrease in
VC and FEV1, an increase in RV and RV/total lung capacity (TLC), and
normal TLC and FEV1/FVC was described by St!anescu [28]. Since an
increase in RV and RV/TLC represents amarker of hyperinﬂation and
air trapping, this pattern has been proposed as an early detector of
peripheral airways disease [29,30]. This alteration has been
observed in the early stages of emphysema, elderly people and
asymptomatic asthma [29,30]. Although the measurement of RV is
an easy-to-perform test, with good reproducibility and low intra-
patient variability, it is commonly envisaged as a rough method of
estimating the function of small airways, mainly because it only
allows a volumetric characterization of premature airway closure
and air trapping, and is not able to detect less evident functional
changes of distal airways conductance and ventilation patterns.
Other spirometric tests are under investigation for the assess-
ment of peripheral airways function. The mean forced expiratory
ﬂow (FEF) between 25% and 75% of FVC (FEF25e75) is one of
the most popular indices of peripheral airways obstruction,
resembling the concavity of the ﬂow-volume curve [31]. However,
its use in clinical practise is limited by physiological variability and
measurement inconsistency issues [32]. Its value as a predictor of
peripheral obstruction has also been questioned following ﬁndings
from the Severe Asthma Research Program of the National Heart
Lung and Blood Institute, which showed a lack of correlation
between FEF25e75 and other indices of air trapping [32].
Among the non-invasive techniques that are proposed to evaluate
small airways function, the forced oscillation technique (FOT) is
gaining increasing importance. FOT uses the non-invasive superim-
position of pressure ﬂuctuations on the airway over the subject’s tidal
breathing. FOT was ﬁrst described by DuBios in 1956 as a method to
characterize respiratory impedance [33]. Similar to FOT, impulse
oscillometry (IOS) is easy toperformand requires only passive patient
cooperation [34]. IOS delivers a regular square wave of pressure 5
timesper second, andhas the advantage of generating a larger sample
during measurements thereby emitting a continuous spectrum of
frequencies that provide a more detailed characterization of respi-
ratory mechanics [35]. IOS has been employed in adults as well as in
preschool asthmatic children to identify lung dysfunction [34,36] and
in the clinical diagnostic testing of individuals with airway hyper-
reactivity and airway obstruction. IOS could also be used during
bronchoprovocation challenges. The advantage of continuous spectra
could be important in conditions of regional non-homogeneities.
A recent paper from Takeda et al. [37] reported that parameters
obtained by IOS are strongly correlated with clinical symptoms and
asthma control in asthmatics. Peripheral and proximal airway
functions, as assessed separately by IOS, independently contribute
to health status, dyspnoea and disease control. IOS also appears to
be a sensitive screening tool for the early detection of bronchial
obstruction [38]. More recently, Oppenheimer et al. proposed that
IOS can be used as a non-invasive tool for assessment of distal
airway function when spirometry is normal [39], and can be
applied to various clinical settings including early diagnosis of
COPD and asthma in clinical remission and occupational/environ-
mental irritant exposure.
The single-breath nitrogen (sbN2) washout test is another non-
invasive tool to assess small airways dysfunction and ventilation
inhomogeneity, and has been used since the 1960s to detect early
closure of peripheral airways. It is based on the detection of
regional differences in ventilation distribution, represented by the
phase III slope of the ﬂow-volume curve following thewashout test.
Towards the end of expiration, an abrupt increase in N2 concen-
tration is observed, which corresponds to the beginning of phase IV.
This is due to the preferential emptying of the apex, following
closure of airways at the base of the lung. The volume at which
phase IV begins is termed closing volume, and reﬂects small
airways abnormalities. Despite being an easily performed and
sensible technique [40], it suffered from poor reproducibility and
predictability in the past [41]. This is no longer a limitation; sbN2
has been employed in studies speciﬁcally addressing the relation-
ship between asthma severity and small airways dysfunction [42].
The multiple breath nitrogen washout (MBW) test measures
functional residual capacity (FRC). Patients with high airways
resistance take longer to clear the nitrogen, and the test can
distinguish between obstructions in the large or small airways.
Dutrieue et al. [43] and Verbanck et al. [44] used the MBW test to
derive the two variables, Scond (index of conductive ventilation
heterogeneity) and Sacin (index of acinar ventilation heteroge-
neity). In asthmatic subjects, the clinical application of MBW
includes evaluation of ventilation heterogeneity after an airway
challenge, and analysis of response differences to inhaled steroids
when comparing non-extraﬁne and extraﬁne particles [45,46].
The inﬂuence of ageing on the ventilation heterogeneity needs
to be taken into consideration. In this scenario, Verbanck and
colleagues recently found that, with respect to the clinical response,
age has a small but consistent effect that needs to be factored in
when using the MBW indices for the detection of small airways
abnormality in disease [47].
The oesophageal balloon technique represents the gold stan-
dard for themeasurement of changes in pleural pressure, and is one
of the most reliable methods to disclose the premature closure of
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small airways [48]. Through the reading of the quasi static pressure
volume curve, and its departure from the exponential curve, the
volume at which closure of the most peripheral airways occurs is
recorded. It is a rather uncomfortable procedure, which cannot be
proposed, in daily clinical practise. With regard to the assessment
of the lung periphery, the oesophageal balloon technique allows
measurement of dynamic compliance. As opposed to static
compliance, which is measured at points of no ﬂow, dynamic
compliance is measured during airﬂow. While in healthy subjects,
dynamic and static compliance are equal, in chronic obstructive
diseases, the ratio between the two decreases as the breathing
frequency rises. This is due to the effect of uneven time constants
on ventilation. The lung compartments with obstructed airways,
and therefore long time constants, continue to ﬁll while the rest of
the lung has begun to exhale. The asynchronous behaviour of
different areas of the lung implies a frequency dependence of
compliance determined by their different time constants. As the
breathing pattern increases, the dynamic compliance falls. This
asynchronous behaviour of lung units has been ascribed primarily
to obstruction in the small airways. Indeed, increased resistance of
peripheral airways is responsible for uneven time constants and,
therefore, for the change in dynamic compliance with breathing
frequency [49e51].
3.2. Biological assessment of peripheral airways
Fractional exhaled nitric oxide (FeNO) is a non-invasivemeasure
of airways inﬂammation. By monitoring the expiratory ﬂow, it is
possible to differentiate selectively between NO from the con-
ducting airways and that coming from the respiratory zone (alve-
olar NO). The detection of alveolar NO is associated with nocturnal
asthma, symptomatic asthmatics and asthmatics with more severe
disease [8,52]. Moreover, alveolar NO is more sensitive to oral than
to inhaled corticosteroids, suggesting that it may represent true
abnormalities of peripheral airways, which are better reached by
systemic drugs than by conventional inhaled formulations [20].
More recently, a method of monitoring the daily ﬂuctuations in
FeNO values with quantiﬁcation over a period of time has been
established, providing information on a subject’s asthma severity
with regard to asthma control and exacerbation risk [53].
Exhaled breath condensate (EBC) obtained by the cooling of the
exhaled breath contains evaporated and condensed components
plus some droplets from the airway lining ﬂuid, but EBC markers of
oxidative stress such as hydrogen peroxide, isoprostanes, nitrogen
oxides, pH, ammonia, prostanoids and leukotrienes are abnormal in
bronchial asthma [54]. Remarkably, both FeNO and 8-isoprostane
concentrations in EBC were positively correlated with small
airways function in asthmatics [55]. However, it is unlikely that one
single marker might be representative of small airways involve-
ment in asthma. EBC is a suitable matrix for metabonomic studies,
which involve measurements of the dynamic multiparametric
metabolic response of living systems to pathophysiological stimuli
or genetic modiﬁcation. The method includes reference analytical
techniques such as mass spectrometry or nuclear magnetic reso-
nance spectroscopy (NMR) [56]. By applying this approach, NMR-
based metabonomic analyses of EBC clearly discriminated
between asthmatic and healthy children, with a 95% success rate in
their classiﬁcation [57]. Whether a metabonomic study of EBC
could reveal a distinct proﬁle of small airways disease in asthma is
currently unknown.
3.3. Imaging assessment of peripheral airways
Computed tomography (CT) has emerged as a useful tool to
assess peripheral airways disease noninvasively in patients with
asthma. The cardinal CT sign of peripheral airways disease in
asthma is the presence of pulmonary decreased attenuation areas,
which are more conspicuous and extensive on expiratory CT scans
[58e60]. They reﬂect air trapping, which may be either secondary
to transient small airway obstruction or spasm or caused by ﬁxed
peripheral remodelling [61e63]. There are two systems for quan-
tifying air trapping on CT: the visual score and the densitometric
analysis. The major disadvantage of a subjective approach is the
variation between observers, and the densitometric analysis,
despite its limitations, has been the technique of choice in recent
scientiﬁc investigations and pharmaceutical trials. Speciﬁcally,
either mean lung density or "850 HU cut-off CT density has been
used to quantify air trapping in asthmatic subjects [63,64].
Quantiﬁcation of air trapping in expiratory studies may provide
additional information regarding response to therapy targeted for
small airways disease that is not readily captured by physiologic
measures [62,65]. This technique was used to compare the relative
efﬁcacy of two different inhaled medications on small airway
hyper-reactivity; small-size inhaled particles prompted a signiﬁ-
cant improvement in air trapping compared with traditional-size
particles [62,65]. These studies demonstrate the potential use of
quantitative imaging in asthmatic patients as a surrogate end point
for small airways remodelling in response to therapies.
Air trapping quantiﬁcation has also been used to deﬁne asth-
matic phenotypes. A recent study by Busacker and colleagues
showed that quantitative CTcan identify a group of individuals with
a high risk of severe disease [64]. Individuals in the group with air
trapping above the median level were signiﬁcantly more likely to
have a history of asthma-related hospitalizations, intensive care
unit visits and/or mechanical ventilation [64].
CT imaging of pulmonary ventilation patterns in patients with
asthma has evolved over the last decade with the introduction of
more sophisticated techniques. Although the direct assessment of
peripheral remodelling by CT measurements is still limited, due to
the difﬁculty in accurately measuring the distal small airways
(typically <2 mm diameter), computer-assisted 3-dimensional
analysis of the airway tree structure is currently advancing the
evaluation of the small airways disease (Fig. 2a and b). By using this
technique in asthmatic patients, it has been shown that the
strongest correlation with airﬂow obstruction was found through
airway wall measurements of the more distal airways [66].
Although current evidence indicates that small airways obstruction
could be routinely assessed using CT scanning, this technique does
have some limitations, including lack of standardization of the
technical parameters of the CT scanner, lack of consensus on the
best index for small-airways disease assessment, and exposure of
subjects to ionizing radiation. Indeed, the regular assessment of
small airway disease via CT imaging is still not part of routine
clinical practise for young asthmatic patients.
In conclusion, clinical trials have demonstrated that several
methodologies are currently available to assess speciﬁcally the
peripheral airways, and to investigate the presence of structural
and functional changes in this bronchial area. These methodologies
differ, however, in terms of accuracy, reliability, accessibility and
cost, and their validation in real-life studies is lacking. From a clin-
ical approach, individualized choices should be made based on the
speciﬁc need and resources available. We propose an algorithm
that takes into account the criteria described above: when assess-
ing peripheral airways in daily practise, parameters of the ﬂow-
volume spirometric curve, such as the FEF25e75, are easily acces-
sible to general practitioners. If peripheral airway involvement is
suspected, referral to a pulmonologist is recommended for
a complete lung function evaluation, including the sbN2 washout
test; IOS may also be useful as an alternative lung function test.
Measurement of alveolar NO, which should always be accessible,
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facilitates the deﬁnition of future risk and the optimal choice of
treatment, and predicts potential beneﬁts. Imaging assessment is
advocated in patients with severe or difﬁcult-to-control asthma.
4. Accessing the peripheral airways: current evidence and
future approaches
Despite the evidence supporting the contribution of peripheral
airways to asthma pathophysiology and clinical manifestations,
very few studies have been designed to address speciﬁcally the
importance of treating the distal part of the lung. Following the
outlawing of chloroﬂuorocarbons (CFC) for environmental reasons,
the development of the new hydroﬂuoroalkane (HFA) inhaler
propellant also enabled the development of extraﬁne particle size
inhaled drug formulations, which means treatment can reach the
peripheral airways. The use of an HFA propellant is necessary, but it
is not the only prerequisite for extraﬁne particle formulations.
Indeed, most HFA pressured metered dose inhalers (pMDIs) on the
market have similar characteristics to the corresponding CFC pMDIs
[67]. To date, there are some single-agent extraﬁne formulations on
the market (beclometasone, ciclesonide, formoterol), and only one
combination product available (beclometasone/formoterol) [68].
Extraﬁne solution pMDIs can deliver compounds with a mass
median aerodynamic diameter that is smaller than that delivered
by other available devices [69]. Thus, these devices are able to
deliver particles to both large and small airways, resulting in
a signiﬁcant increase in peripheral airways drug deposition with
respect to the delivered dose [70].
Initial studies evaluating the efﬁcacy of extraﬁne formulations in
asthmatic patients were performed with inhaled corticosteroids
(ICS) alone. These studies revealed that ICS extraﬁne formulations
were superior to non-extraﬁne formulations in modulating func-
tional and inﬂammatory parameters, reﬂecting small airway
abnormalities [45,62,71]. The relative superiority of extraﬁne
formulations was also observed for clinical outcomes that are
not directly linked to small airways. Indeed, it was calculated that
2.6-fold non-extraﬁne beclometasone (BDP) is required to achieve
the same improvement in FEV1 as extra-ﬁne HFAeBDP [72].
Moreover, in an open-label, 12-month randomised controlled trial,
Juniper et al. showed that in asthmatic patients previously treated
with non-extraﬁne CFCeBDP and switching to equipotent doses of
extra-ﬁne HFAeBDP (half of the dose of non-extra-ﬁne CFCeBDP),
there was a signiﬁcant improvement in asthma quality of life
compared with those patients who continued to receive non-
extraﬁne CFCeBDP [73].
More recent studies were conducted using a ﬁxed combination
of extraﬁne beclometasone/formoterol (BDP/F). Huchon et al.
showed that extraﬁne BDP/F delivered by an HFA pMDI (400/
24 mcg) was superior in improving asthma control over 24 weeks
of treatment to the combination of the same drugs formulated as
larger non-extraﬁne agents, at equipotent doses (1000 mcg
BDP þ 24 < mcg F) [74]. Moreover, in two large studies (>200
patients in each study), Papi and co-workers [75,76] reported that
the extraﬁne combination of BDP/F was comparable in terms of
lung function improvement (as measured by morning peak expi-
ratory ﬂow changes) to the non-extraﬁne combinations of an
ICS with a long-acting b2 agonist (LABA), budesonide/formoterol
(BUD/F) and ﬂuticasone/salmeterol (FP/S), at equipotent doses.
Achieving and maintaining asthma control is a major goal of
asthma care. A real life observational study was conducted by
Müller et al. to compare the asthma control efﬁcacy of a BDP/F pMDI
extraﬁne formulation vs BUD/F and FP/S combinations (non-extra-
ﬁne formulations, both delivered as dry powder inhalers [DPIs]). In
this real life setting, the proportion of patients achieving asthma
control was signiﬁcantly higher in the BDP/F extraﬁne group than in
the non-extraﬁne BUD/F or FP/S group, and this was achieved with
a signiﬁcantly lower ICSmean daily dose [77]. Thiswas conﬁrmed in
a recently published large observational study, showing that the
extraﬁne BDP/F combination resulted in better asthma control and
quality of life compared to non-extraﬁne formulations [78].
However, it remains to be established whether the addictive effect
of extraﬁne formulations compared to no extraﬁne formulations on
asthma control is related to the small airways targeting or whether
may represent a consequence of a better distribution of the deliv-
ered drugs throughout the bronchial tree.
When functional parameters more related to peripheral airways
abnormalities were considered, 12 weeks of extraﬁne BDP/F
combination treatment was signiﬁcantly superior to an equipotent
dose of the non-extraﬁne FP/S combination in improving air trap-
ping (without increased risk of systemic effects), which was
measured by a reduction in FVC [75]. In addition, 12 weeks of
Fig. 2. Quantitative analysis of airway lumen and wall area in a young patient with
severe asthma. (a) Multidetector CT permits reconstruction of airway tree using
proprietary software (MEVIS Airway Examiner) which automatically provides bron-
chial measurements for selected pathways. (b) Orthogonal image through the airway
provides measurement of airway dimensions. The airways are moderately thick-
walled. (Courtesy of Michael Schmidt, Fraunhofer MEVIS, Bremen, Germany).
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extraﬁne BDP/F combination treatment tended to be signiﬁcantly
superior to equipotent doses of non-extraﬁne FP/S in improving
closing capacity measured by the sbN2 washout test [79]. These
latter results provide direct evidence of the superiority of the
extraﬁne ICS/LABA combinations compared to the non-extraﬁne
combinations in improving small-airways function, possibly
linked to the higher proportion of small particle delivered by
extraﬁne formulations able to reach the more peripheral airway
tract [80]. However, non-extraﬁne formulations are also able to
signiﬁcantly modify functional parameters reﬂecting small airways
dysfunctions [81]. This ﬁnding is in line with the fact that also non-
extraﬁne formulations can deliver a proportion of small particle
able to reach the periphery of the lung. Thus, despite the evidence
that extraﬁne formulations are more potent as compared to non
extraﬁne formulations in targeting peripheral airways (peripheral
deposition of the BDP/F extraﬁne combination is 2.55 fold higher
compared to the FP/S non-extraﬁne combination) [80,82], the
relative contribution of the modulation of peripheral airway
abnormalities on clinical outcomes is still unclear. Head to head
(extraﬁne vs non-extraﬁne) randomized controlled studies are
needed to evaluate whether changes in small-airway abnormalities
correlate with improvement in clinical outcomes. Similarly, and
even more importantly, clinical trials are needed to evaluate
whether extraﬁne formulations would represent a speciﬁc thera-
peutic option for speciﬁc groups of patients characterised by
enhanced small airway dysfunctions.
5. Conclusions
Evidence of substantial and severe inﬂammation in the periph-
eral airways of patientswith asthmahas highlighted the importance
of the assessment and treatment of this airway compartment.
Moreover, several studies document better correlations between
inﬂammatory, functional and imaging parameters reﬂecting small
airway and both asthma control scores and quality of life. Recent
data, coming from real-life studies show that extraﬁne formulations
result in better asthma control compared to non-extraﬁne formu-
lations. Whether this achievement is the result of the broader
distribution of the delivered compounds through the airways or
whether it is due to speciﬁc targeting of small airway dysfunction is
still largely unknown, and appropriately designed studies are war-
ranted. Relative inaccessibility of the peripheral airways and inad-
equacy of routine diagnostic methods to explore the more
peripheral airway compartments has limited both the clinical
research on small airways and the clinical assessment of small
airways in daily clinical practise. However, in particular when
managing cases of difﬁcult-to-treat/uncontrolled asthma, we
propose that physicians perform lung function assessments to
classify the severity of asthma, andassess peripheral airway function
and inﬂammation to detect the involvement of this site, in order to
evaluate the possibility of individualized therapeutic decisions. It is
no longer acceptable to deﬁne the peripheral airways as the “silent
zone” and to forget their crucial function in respiratory system. The
“silent zone” speaks loudly, but only if we listen carefully.
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